jili slot 50 deposit
2025-01-11   

jili slot 50 deposit Spotify Revealed Its Most-Streamed Holiday Songs By Decade, Which Has Caused A Generational War Between UsersParty City to close its stores as company files for bankruptcy LOS ANGELES (AP) — Party City announced that it's going to “wind down” its retail and wholesale operations as it prepares to shutter nearly 700 stores nationwide. The company said Saturday it has also filed for Chapter 11 bankruptcy protection "to maximize value for the benefit of the company’s stakeholders.” The New Jersey-based retailer said it will keep more than 95% of its 12,000 employees to help with the process of closing down. Customers have flocked to Party City for Halloween costumes, favors for children’s birthday parties and decorations for New Year’s Eve celebrations for nearly 40 years. It has faced growing competition from Walmart and Target and from occasion-based pop-up stores such as Spirit Halloween. A million taxpayers will soon receive up to $1,400 from the IRS. Who are they and why now? Approximately 1 million taxpayers will automatically receive special payments of up to $1,400 from the IRS in the coming weeks. The money will be directly deposited into eligible people’s bank accounts or sent in the mail by a paper check. Most people shouldn't get their hopes up about receiving the cash. The IRS says it’s distributing about $2.4 billion to taxpayers who failed to claim a Recovery Rebate Credit on their 2021 tax returns after missing one of the COVID stimulus payments or receiving less than the full amount. The IRS says most taxpayers eligible for the federal stimulus payments received them. Bluesky finds with growth comes growing pains — and bots Bluesky has seen its user base soar since the U.S. presidential election, boosted by people seeking refuge from Elon Musk’s X, or wanting an alternative to Meta’s Threads and its algorithms. The platform grew out of the company then known as Twitter and was eventually intended to replace it. While this is still very much a pie in the sky, Bluesky’s growth trajectory could make it a serious competitor to other social platforms. With growth, though, comes growing pains. It’s not just human users who’ve been flocking to Bluesky but also bots, including those designed to create partisan division or direct users to junk websites. 'Sonic 3' bests 'Mufasa: The Lion King' at the box office NEW YORK (AP) — In the holiday season battle of big-budget family movies, Paramount Pictures’ “Sonic the Hedgehog 3” sped past the Walt Disney Co.’s “Mufasa: The Lion King” to take the top spot at the box office. The results came just ahead of the lucrative Christmas corridor in theaters. According to studio estimates, “Sonic the Hedgehog 3” debuted with $62 million in ticket sales over the weekend. “Mufasa,” however, was humbled in its opening weekend, coming in notably shy of expectations. It returned just $35 million in domestic ticket sales. Amazon and Starbucks workers are on strike. Trump might have something to do with it Amazon delivery drivers and Starbucks baristas are on strike in a handful of U.S. cities as they seek to exert pressure on the two major companies to recognize them as unionized employees or to meet demands for an inaugural labor contract. Strikes during busy periods like the holidays can help unions exercise leverage during negotiations or garner support from sympathetic consumers. One expert says he thinks workers at both companies are “desperate” to make progress before President-elect Donald Trump can appoint a Republican majority to the National Labor Relations Board. Workers at Starbucks, Amazon and some other prominent consumer brands are fighting for their first contracts after several locations voted to unionize. Farmers are still reeling months after Hurricane Helene ravaged crops across the South LYONS, Ga. (AP) — Farmers in Georgia are still reeling more than two months after Hurricane Helene blew away cotton, destroyed ripened squash and cucumbers and uprooted pecan trees and timber. Agribusinesses in other Southern states saw costly damage as well. The University of Georgia estimates the September storm inflicted $5.5 billion in direct losses and indirect costs in Georgia alone. In rural Toombs County, Chris Hopkins just finished harvesting his ravaged cotton crop and figures he lost half of it, costing him about $430,000. Poultry grower Jeffrey Pridgen in Georgia's Coffee County had four of his 12 chicken houses destroyed and others badly damaged. Farmers say more government disaster assistance is needed. Ex-OpenAI engineer who raised legal concerns about the technology he helped build has died Suchir Balaji, a former OpenAI engineer and whistleblower who helped train the artificial intelligence systems behind ChatGPT and later said he believed those practices violated copyright law, has died, according to his parents and San Francisco officials. He was 26. He was well-regarded by colleagues at the San Francisco company, where a co-founder this week called him one of OpenAI’s strongest contributors who was essential to developing some of its products. But he grew disillusioned with the company and told The Associated Press this fall he would “try to testify” in copyright infringement cases against it. Federal Reserve's preferred inflation gauge shows price pressures eased last month WASHINGTON (AP) — An inflation gauge that is closely watched by the Federal Reserve barely rose last month in a sign that price pressures cooled after two months of sharp gains. Prices rose just 0.1% from October to November. Excluding the volatile food and energy categories, prices also ticked up just 0.1%, after two months of outsize 0.3% gains. The milder inflation figures arrived two days after Federal Reserve officials, led by Chair Jerome Powell, rocked financial markets by revealing that they now expect to cut their key interest rate just two times in 2025, down from four in their previous estimate. Albania to close TikTok for a year blaming it for promoting violence among children TIRANA, Albania (AP) — Albania’s prime minister says the government will shut down video service TikTok for one year, blaming it for inciting violence and bullying, especially among children. Albanian authorities held 1,300 meetings with teachers and parents following the stabbing death of a teenager in mid-November by another teenager following a quarrel that started on TikTok. Prime Minister Edi Rama, speaking at a meeting with teachers and parents, said TikTok “would be fully closed for all. ... There will be no TikTok in the Republic of Albania.” Rama says the ban will begin sometime next year. Albanian children comprise the largest group of TikTok users in the country, according to domestic researchers. Stock market today: Wall Street rises to turn a dismal week into just a bad one NEW YORK (AP) — U.S. stocks rose to turn what would have been one of the market’s worst weeks of the year into just a pretty bad one. The S&P 500 rallied 1.1% Friday to shave its loss for the week down to 2%. The Dow Jones Industrial Average jumped nearly 500 points, and the Nasdaq composite gained 1%. A report said a measure of inflation the Federal Reserve likes to use was slightly lower last month than expected. It’s an encouraging signal after the Fed shocked markets Wednesday by saying worries about inflation could keep it from cutting interest rates in 2025 as much as earlier thought.Imagine climbing to the top of Hollywood, making millions and living a life that screams "success" – then walking away from it all to live in a trailer park. It sounds like the plot of a quirky indie film. Still, it's the real-life story of Tom Shadyac, the director behind some of Hollywood's most iconic comedies, including Ace Ventura: Pet Detective and Bruce Almighty. Shadyac didn't just flirt with success ; he made a fortune off it. His films have grossed over $2 billion worldwide. He directed blockbusters like The Nutty Professor and Liar Liar, working with megastars like Jim Carrey and Eddie Murphy. Shadyac's net worth was around $50 million at his peak. According to Celebrity Net Worth in 2024, he owned a sprawling 17,000-square-foot mansion, a private jet and enough exotic cars to make Jay Leno jealous. And yet, Shadyac claims, "I was my least successful when I ‘had it all.'" Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today. ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. The deadline to invest and receive your shares this year is 12/20. Join 30,000+ shareholders and invest at $0.26/share today. So, what makes a man trade in a mansion for a 1,000-square-foot double-wide in a Malibu trailer park? Shadyac started in Hollywood as a joke writer for Bob Hope, but his big break came with Ace Ventura: Pet Detective in 1994. The film, made on a modest $15 million budget, grossed over $100 million and turned Jim Carrey into a household name. From there, Shadyac's career skyrocketed. He directed hit after hit: The Nutty Professor ($273 million worldwide), Liar Liar ($302 million) and Bruce Almighty ($485 million). For Bruce Almighty, Shadyac even negotiated a piece of the back-end profits, raking in over $30 million for that film alone. At the time, Shadyac was living the ultimate Hollywood dream. But it wasn't long before the dream started feeling more like a trap. See Also: It’s no wonder Jeff Bezos holds over $70 million in art — this alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. Here’s how everyday investors are getting started. In 2007, Shadyac's life took a dramatic turn. A biking accident left him with a severe concussion and chronic symptoms like migraines and hypersensitivity to light and sound. For months, he was essentially confined to his mansion, his mental health spiraling. He later admitted, "I felt suicidal at points. It was a disaster." During this dark time, Shadyac had an epiphany. His extravagant lifestyle – private jets, luxury cars, a massive home – felt hollow. The things that were supposed to signify success had become "trappings." Shadyac decided to give away his fortune in a move that shocked Hollywood. He sold his mansion, his cars and his jet. He then started donating millions to causes close to his heart , like homelessness, environmental conservation and animal welfare. He even helped fund a homeless shelter in Charlottesville, Virginia and supported St. Jude's Children's Research Hospital. Trending: Are you rich? Here’s what Americans think you need to be considered wealthy. Shadyac moved into a trailer park in Malibu, where his modest home stands in dramatic contrast to the lives of Hollywood's elite. He says the decision was liberating: "The more I give away, the wealthier I feel. For everything I ‘gave up,' so much more was returned." Shadyac didn't just change his ZIP code; he changed his entire worldview. In 2011, he directed I Am, a documentary exploring two fundamental questions: "What's wrong with the world?" and "What can we do about it?" The film examines the pursuit of happiness and the consequences of excessive materialism. He executive-produced Happy, another documentary examining what brings joy across different cultures. These projects reflect Shadyac's belief that life isn't about accumulating wealth but building connections and giving back. Trending: These five entrepreneurs are worth $223 billion – they all believe in one platform that offers a 7-9% target yield with monthly dividends As he puts it: "No one is ever looking to have a more robust IRA when they are on their deathbed. They are saying, ‘I am so happy that I had the opportunity to love this family, to be a part of something.'" Shadyac's story reminds us that success isn't just about what you earn; it's about what you give back. While his Hollywood peers chase box office records and six-figure paychecks, Shadyac has found peace in simplicity. It's easy to dismiss his decision as extreme, but Shadyac sees it differently. To him, living a life centered on giving and purpose is far more fulfilling than jet-setting and luxury cars. "The trappings of fame and fortune are exactly that – a trapping," he says. From the director's chair to a double-wide in Malibu, Tom Shadyac has proved that happiness isn't about having it all but knowing what truly matters. Read Next: Many are using retirement income calculators to check if they’re on pace — here’s a breakdown on what’s behind this formula. Groundbreaking trading app with a ‘Buy-Now-Pay-Later' feature for stocks tackles the $644 billion margin lending market – here’s how to get equity in it with just $100 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The Dyson V15 Detect Plus cordless vacuum is at a record low price of $599, which reflects a 20% discount from its original price of $749 . This vacuum is designed for powerful and intelligent whole-home deep cleaning (with a green laser) which is perfect if you’re looking to maintain a spotless living environment. See at Amazon When you purchase an item from Amazon during this early Black Friday sale, you will benefit from a price guarantee—if the price drops further during the Black Friday period, Amazon will refund the difference. Additionally, Amazon has extended its return policy until January 31, 2025, which is especially convenient for holiday gift-giving. Powerful Cordless Vacuum One of the much appreciated features of the Dyson V15 Detect Plus is its innovative laser technology : the vacuum is equipped with a Laser Slim Fluffy cleaner head which illuminates invisible dust and debris on hard floors. This feature allows users to see particles that would otherwise go unnoticed and ensure a more thorough clean. The laser highlights fine dust and makes it easier to target and remove it during cleaning sessions. The advanced whole-machine filtration system of the Dyson vacuum captures 99.99% of particles as small as 0.3 microns and expels cleaner air back into your home. In terms of performance, the Dyson V15 Detect Plus boasts up to 60 minutes of run time (that you can track on the LCD screen), thanks to its advanced battery technology. The power trigger helps maximize energy efficiency by using power only when needed and extends the vacuum’s operational time. Moreover, the vacuum intelligently adapts its suction power based on the type and amount of debris detected for optimal cleaning performance across various surfaces. The Dyson V15 Detect Plus on sale at Amazon features 2 advanced cleaner heads: the Laser Slim Fluffy head for hard floors and the Digital Motorbar for deep cleaning carpets. The Digital Motorbar is designed to tackle all floor types effectively and uses stiff nylon bristles that penetrate deep into carpets to remove ground-in dirt while also being gentle on hard surfaces. This cleaner head also incorporates anti-tangle technology that detangles long hair and pet hair as you clean. To see the deal, here it is: See at AmazonPALERMO, Calif. (AP) — Two children were wounded in a shooting Wednesday at a small religious K-8 school in Northern California and the shooter died from a suspected self-inflicted gunshot, sheriff’s officials said. The children’s conditions were not immediately known. The shooting occurred Wednesday afternoon at the Feather River School of Seventh-Day Adventists, a private, K-8 school in Palermo, a community of 5,500 people about 65 miles (104 km) north of Sacramento. Related Articles National News | Abandoned mines in the US pose dangers to people and property when land gives way National News | Dog food recalled in 7 states for salmonella risk after puppy litter gets sick, FDA says National News | White House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaign National News | Powell: Fed’s independence from politics is vital to its interest rate decisions National News | United Healthcare CEO kept a low public profile. Then he was shot to death in New York Butte County Sheriff Kory L. Honea said the 911 calls reported “an individual on campus who had fired shots at students,” and said that the shooter did not appear to have a connection to the school. The motive was not immediately known, he continued. One student was flown to a nearby hospital, Honea said. Authorities rushed students to the Oroville Church of the Nazarene to be reunited with their families, the sheriff’s office said. The school has been open since 1965 and caters to fewer than three dozen children, according to its website.California to consider requiring mental health warnings on social media sites

Supreme Court to weigh bans on puberty blockers, hormones for trans teensRecord Revenues as Global Logistics Network Expands WATERLOO, Ontario and ATLANTA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The Descartes Systems Group Inc. (TSX:DSG) (Nasdaq:DSGX) announced its financial results for its fiscal 2025 third quarter (Q3FY25). All financial results referenced are in United States (US) currency and, unless otherwise indicated, are determined in accordance with US Generally Accepted Accounting Principles (GAAP). “Our business has grown organically while we've added complementary solutions to our Global Logistics Network by way of acquisition,” said Edward J. Ryan, Descartes’ CEO. “We listen to our customers about where best to invest to help them meet the many logistics and supply chain challenges they're facing, which contributed to us completing two acquisitions this past quarter. The global trade landscape remains highly uncertain and complex for our customers, especially with potential upcoming changes to tariffs and sanctions and the resulting impact on trade. As always, our goal is to help our customers manage this complexity so that they can continue to focus on their core businesses.” Q3FY25 Financial Results As described in more detail below, key financial highlights for Descartes’ Q3FY25 included: Adjusted EBITDA and Adjusted EBITDA as a percentage of revenues are non-GAAP financial measures provided as a complement to financial results presented in accordance with GAAP. We define Adjusted EBITDA as earnings before interest, taxes, depreciation, amortization, stock-based compensation (for which we include related fees and taxes) and other charges (for which we include restructuring charges, acquisition-related expenses, and contingent consideration incurred due to better-than-expected performance from acquisitions). These items are considered by management to be outside Descartes' ongoing operational results. We define Adjusted EBITDA as a percentage of revenues as the quotient, expressed as a percentage, from dividing Adjusted EBITDA for a period by revenues for the corresponding period. A reconciliation of Adjusted EBITDA and Adjusted EBITDA as a percentage of revenues to net income determined in accordance with GAAP is provided later in this release. The following table summarizes Descartes' results in the categories specified below over the past 5 fiscal quarters (unaudited; dollar amounts, other than per share amounts, in millions): Year-to-Date Financial Results As described in more detail below, key financial highlights for Descartes’ nine-month period ended October 31, 2024 (9MFY25) included: Cash provided by operating activities of $158.5 million, up 1% from $156.9 million in 9MFY24. Cash provided by operating activities was negatively impacted in 9MFY25 by the payment of $25.0 million in contingent acquisition consideration for previously completed deals, which was not accrued for at the time of acquisition; The following table summarizes Descartes’ results in the categories specified below over 9MFY25 and 9MFY24 (unaudited, dollar amounts in millions): Cash Position At October 31, 2024, Descartes had $181.3 million in cash. Cash decreased by $71.4 million in Q3FY25 and $139.7 million in 9MFY25. The table set forth below provides a summary of cash flows for Q3FY25 and 9MFY25 in millions of dollars: Acquisition of MyCarrierPortal On September 17, 2024, Descartes acquired all of the shares of Assure Assist, Inc., doing business as MyCarrierPortal (“MCP”), a leading provider of carrier onboarding and risk monitoring solutions for the trucking industry. The purchase price for the acquisition was approximately $22.5 million, net of cash acquired, which was funded from cash on hand, plus potential performance-based consideration of up to $6.0 million based on MCP achieving revenue-based targets over the first two years post-acquisition. Acquisition of Sellercloud On October 11, 2024, Descartes acquired all of the shares of Sellercloud LLC and certain assets of Sellercloud Europe Ltd. (collectively referred to as “Sellercloud”), a leading provider of omnichannel ecommerce solutions. The purchase price for the acquisition was approximately $110.2 million, net of cash acquired, which was funded from cash on hand, plus potential performance-based consideration of up to $20.0 million based on Sellercloud achieving revenue-based targets over the first two years post-acquisition. Conference Call Members of Descartes' executive management team will host a conference call to discuss the company's financial results at 5:30 p.m. ET on Tuesday, December 3, 2024. Designated numbers are +1 289 514 5100 and +1 800 717 1738 for Toll-Free in North America, using conference ID 07584. The company will simultaneously conduct an audio webcast on the Descartes website at www.descartes.com/descartes/investor-relations. Phone conference dial-in or webcast login is required approximately 10 minutes beforehand. Replays of the conference call will be available until December 10, 2024, by dialing +1 289 819 1325 or Toll-Free for North America using +1 888 660 6264 with Playback Passcode: 07584#. An archived replay of the webcast will be available at www.descartes.com/descartes/investor-relations. About Descartes Descartes (Nasdaq:DSGX) (TSX:DSG) is the global leader in providing on-demand, software-as-a-service solutions focused on improving the productivity, security and sustainability of logistics-intensive businesses. Customers use our modular, software-as-a-service solutions to route, track and help improve the safety, performance and compliance of delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world’s largest, collaborative multimodal logistics community. Our headquarters are in Waterloo, Ontario, Canada and we have offices and partners around the world. Learn more at www.descartes.com , and connect with us on LinkedIn and X (Twitter ). Descartes Investor Contact Laurie McCauley (519) 746-2969 investor@descartes.com Cautionary Statement Regarding Forward-Looking Statements This release may contain forward-looking information within the meaning of applicable securities laws ("forward-looking statements") that relates to Descartes' expectations concerning future revenues and earnings, and our projections for any future reductions in expenses or growth in margins and generation of cash; our assessment of the potential impact of geopolitical events, such as the ongoing conflict between Russia and Ukraine (the “Russia-Ukraine Conflict”), and between Israel and Hamas (“Israel-Hamas Conflict”), or other potentially catastrophic events, on our business, results of operations and financial condition; continued growth and acquisitions including our assessment of any increased opportunity for our products and services as a result of trends in the logistics and supply chain industries; rate of profitable growth and Adjusted EBITDA margin operating range; demand for Descartes' solutions; growth of Descartes' Global Logistics Network (“GLN”); customer buying patterns; customer expectations of Descartes; development of the GLN and the benefits thereof to customers; and other matters. These forward-looking statements are based on certain assumptions including the following: global shipment volumes continuing at levels generally consistent with those experienced historically; the Russia-Ukraine Conflict and Israel-Hamas Conflict not having a material negative impact on shipment volumes or on the demand for the products and services of Descartes by its customers and the ability of those customers to continue to pay for those products and services; countries continuing to implement and enforce existing and additional customs and security regulations relating to the provision of electronic information for imports and exports; countries continuing to implement and enforce existing and additional trade restrictions and sanctioned party lists with respect to doing business with certain countries, organizations, entities and individuals; Descartes' continued operation of a secure and reliable business network; the stability of general economic and market conditions, currency exchange rates, and interest rates; equity and debt markets continuing to provide Descartes with access to capital; Descartes' continued ability to identify and source attractive and executable business combination opportunities; Descartes' ability to develop solutions that keep pace with the continuing changes in technology, and our continued compliance with third party intellectual property rights. These assumptions may prove to be inaccurate. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Descartes, or developments in Descartes' business or industry, to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, Descartes' ability to successfully identify and execute on acquisitions and to integrate acquired businesses and assets, and to predict expenses associated with and revenues from acquisitions; the impact of network failures, information security breaches or other cyber-security threats; disruptions in the movement of freight and a decline in shipment volumes including as a result of contagious illness outbreaks; a deterioration of general economic conditions or instability in the financial markets accompanied by a decrease in spending by our customers; the ability to attract and retain key personnel and the ability to manage the departure of key personnel and the transition of our executive management team; changes in trade or transportation regulations that currently require customers to use services such as those offered by Descartes; changes in customer behaviour and expectations; Descartes’ ability to successfully design and develop enhancements to our products and solutions; departures of key customers; the impact of foreign currency exchange rates; Descartes' ability to retain or obtain sufficient capital in addition to its debt facility to execute on its business strategy, including its acquisition strategy; disruptions in the movement of freight; the potential for future goodwill or intangible asset impairment as a result of other-than-temporary decreases in Descartes' market capitalization; and other factors and assumptions discussed in the section entitled, "Certain Factors That May Affect Future Results" in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities commissions across Canada, including Descartes' most recently filed Management's Discussion and Analysis. If any such risks actually occur, they could materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purpose of providing information about management's current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. Reconciliation of Non-GAAP Financial Measures - Adjusted EBITDA and Adjusted EBITDA as a percentage of revenues We prepare and release quarterly unaudited and annual audited financial statements prepared in accordance with GAAP. We also disclose and discuss certain non-GAAP financial information, used to evaluate our performance, in this and other earnings releases and investor conference calls as a complement to results provided in accordance with GAAP. We believe that current shareholders and potential investors in our company use non-GAAP financial measures, such as Adjusted EBITDA and Adjusted EBITDA as a percentage of revenues, in making investment decisions about our company and measuring our operational results. The term “Adjusted EBITDA” refers to a financial measure that we define as earnings before certain charges that management considers to be non-operating expenses and which consist of interest, taxes, depreciation, amortization, stock-based compensation (for which we include related fees and taxes) and other charges (for which we include restructuring charges, acquisition-related expenses, and contingent consideration incurred due to better-than-expected performance from acquisitions). Adjusted EBITDA as a percentage of revenues divides Adjusted EBITDA for a period by the revenues for the corresponding period and expresses the quotient as a percentage. Management considers these non-operating expenses to be outside the scope of Descartes’ ongoing operations and the related expenses are not used by management to measure operations. Accordingly, these expenses are excluded from Adjusted EBITDA, which we reference to both measure our operations and as a basis of comparison of our operations from period-to-period. Management believes that investors and financial analysts measure our business on the same basis, and we are providing the Adjusted EBITDA financial metric to assist in this evaluation and to provide a higher level of transparency into how we measure our own business. However, Adjusted EBITDA and Adjusted EBITDA as a percentage of revenues are non-GAAP financial measures and may not be comparable to similarly titled measures reported by other companies. Adjusted EBITDA and Adjusted EBITDA as a percentage of revenues should not be construed as a substitute for net income determined in accordance with GAAP or other non-GAAP measures that may be used by other companies, such as EBITDA. The use of Adjusted EBITDA and Adjusted EBITDA as a percentage of revenues does have limitations. In particular, we have completed seven acquisitions since the beginning of fiscal 2024 and may complete additional acquisitions in the future that will result in acquisition-related expenses and restructuring charges. As these acquisition-related expenses and restructuring charges may continue as we pursue our consolidation strategy, some investors may consider these charges and expenses as a recurring part of operations rather than expenses that are not part of operations. The table below reconciles Adjusted EBITDA and Adjusted EBITDA as a percentage of revenues to net income reported in our unaudited Consolidated Statements of Operations for Q3FY25, Q2FY25, Q1FY25, Q4FY24, and Q3FY24, which we believe is the most directly comparable GAAP measure. The table below reconciles Adjusted EBITDA and Adjusted EBITDA as a percentage of revenues to net income reported in our unaudited Consolidated Statements of Operations for 9MFY25 and 9MFY24, which we believe is the most directly comparable GAAP measure. The Descartes Systems Group Inc. Condensed Consolidated Balance Sheets (US dollars in thousands; US GAAP; Unaudited) The Descartes Systems Group Inc. Consolidated Statements of Operations (US dollars in thousands, except per share and weighted average share amounts; US GAAP; Unaudited) The Descartes Systems Group Inc. Condensed Consolidated Statements of Cash Flows (US dollars in thousands; US GAAP; Unaudited)

NEW YORK (AP) — U.S. stocks tiptoed to more records amid a mixed Tuesday of trading, tacking a touch more onto what’s already been a stellar year so far. The S&P 500 edged up by 2 points, or less than 0.1%, to set an all-time high for the 55th time this year. It’s climbed in 10 of the last 11 days and is on track for one of its best years since the turn of the millennium. The Dow Jones Industrial Average slipped 76 points, or 0.2%, while the Nasdaq composite added 0.4% to its own record set a day earlier. AT&T rose 4.6% after it boosted its profit forecast for the year. It also announced a $10 billion plan to send cash to its investors by buying back its own stock, while saying it expects to authorize another $10 billion of repurchases in 2027. On the losing end of Wall Street was U.S. Steel, which fell 8%. President-elect Donald Trump reiterated on social media that he would not let Japan’s Nippon Steel take over the iconic Pennsylvania steelmaker. Nippon Steel announced plans last December to buy the Pittsburgh-based steel producer for $14.1 billion in cash, raising concerns about what the transaction could mean for unionized workers, supply chains and U.S. national security. Earlier this year, President Joe Biden also came out against the acquisition. Tesla sank 1.6% after a judge in Delaware reaffirmed a previous ruling that the electric car maker must revoke Elon Musk’s multibillion-dollar pay package. The judge denied a request by attorneys for Musk and Tesla’s corporate directors to vacate her ruling earlier this year requiring the company to rescind the unprecedented pay package. All told, the S&P 500 rose 2.73 points to 6,049.88. The Dow fell 76.47 to 44,705.53, and the Nasdaq composite gained 76.96 to 19,480.91. In the bond market, Treasury yields held relatively steady after a report showed U.S. employers were advertising slightly more job openings at the end of October than a month earlier. Continued strength there would raise optimism that the economy could remain out of a recession that many investors had earlier worried was inevitable. The yield on the 10-year Treasury rose to 4.23% from 4.20% from late Monday. Yields have seesawed since Election Day amid worries that Trump’s preferences for lower tax rates and bigger tariffs could spur higher inflation along with economic growth. But traders are still confident the Federal Reserve will cut its main interest rate again at its next meeting in two weeks. They’re betting on a nearly three-in-four chance of that, according to data from CME Group. Lower rates can give the economy more juice, but they can also give inflation more fuel. The key report this week that could guide the Fed’s next move will arrive on Friday. It’s the monthly jobs report , which will show how many workers U.S. employers hired and fired during November. It could be difficult to parse given how much storms and strikes distorted figures in October. Based on trading in the options market, Friday’s jobs report appears to be the biggest potential market mover until the Fed announces its next decision on interest rates Dec. 18, according to strategists at Barclays Capital. In financial markets abroad, the value of South Korea’s currency fell 1.1% against the U.S. dollar following a frenetic night where President Yoon Suk Yeol declared martial law and then later said he’d lift it after lawmakers voted to reject military rule. Stocks of Korean companies that trade in the United States also fell, including a 1.6% drop for SK Telecom. Japan’s Nikkei 225 jumped 1.9% to help lead global markets. Some analysts think Japanese stocks could end up benefiting from Trump’s threats to raise tariffs , including for goods coming from China . Trade relations between the U.S. and China took another step backward after China said it is banning exports to the U.S. of gallium, germanium, antimony and other key high-tech materials with potential military applications. The counterpunch came swiftly after the U.S. Commerce Department expanded the list of Chinese technology companies subject to export controls to include many that make equipment used to make computer chips, chipmaking tools and software. The 140 companies newly included in the so-called “entity list” are nearly all based in China. In China, stock indexes rose 1% in Hong Kong and 0.4% in Shanghai amid unconfirmed reports that Chinese leaders would meet next week to discuss planning for the coming year. Investors are hoping it may bring fresh stimulus to help spur growth in the world’s second-largest economy. In France, the CAC 40 rose 0.3% amid continued worries about politics in Paris , where the government is battling over the budget. AP Business Writers Yuri Kageyama and Matt Ott contributed.

Eagles WR DeVonta Smith (hamstring) ruled out vs. Rams(All times Eastern) Schedule subject to change and/or blackouts Tuesday, Nov. 26 CANADIAN HOCKEY LEAGUE 7 p.m. NHLN — CHL/USA Prospects Challenge: From London, Ontario COLLEGE BASKETBALL (MEN’S) 1:30 p.m. CBSSN — Sunshine Slam Beach Bracket: TBD, Third-Place Game, Daytona Beach, Fla. 2 p.m. TBS — Players Era Festival: San Diego St. vs. Creighton, Las Vegas 3:30 p.m. ESPN2 — Maui Invitational: TBD, Consolation Semifinal, Maui, Hawaii People are also reading... 4 p.m. CBSSN — Sunshine Slam Beach Bracket: TBD, Championship, Daytona Beach, Fla. 4:30 p.m. TBS — Oregon vs. Texas A&M, Las Vegas 6 p.m. CBSSN — Sunshine Slam Ocean Bracket: Wyoming vs. Tulane, Semifinal, Riviera Maya, Mexico ESPN — Maui Invitational: TBD, Semifinal, Maui, Hawaii 6:30 p.m. ESPNU — W. Kentucky at Kentucky 7 p.m. ACCN — Manhattan at Virginia FS1 — Wagner at Georgetown TRUTV — Acrisure Holiday Invitational: Grand Canyon vs. Stanford, Semifinal, Palm Springs, Calif. 8 p.m. BTN — SC-Upstate at Iowa TBS — Players Era Festival: Houston vs. Alabama, Las Vegas 8:30 p.m. CBSSN — Sunshine Slam Ocean Bracket: Loyola Marymount vs. Belmont, Semifinal, Riviera Maya, Mexico ESPNU — Maui Invitational: TBD, Consolation Semifinal, Maui, Hawaii 9 p.m. ESPN — Vegas Showdown: Kansas vs. Duke, Las Vegas 9:30 p.m. TRUTV — Acrisure Holiday Invitational: California Baptist vs. SMU, Semifinal, Palm Springs, Calif. 10 p.m. BTN — S. Utah at UCLA 10:30 p.m. TBS — Players Era Festival: Rutgers vs. Notre Dame, Las Vegas 11 p.m. ESPN — Maui Invitational: TBD, Semifinal, Maui, Hawaii 11:30 p.m. ESPNU — Vegas Showdown: Seattle vs. Furman, Las Vegas Midnight TRUTV — Acrisure Holiday Invitational: Fresno St. vs. Washington St., Semifinal, Palm Springs, Calif. COLLEGE BASKETBALL (WOMEN’S) 2 p.m. TRUTV — Acrisure Holiday Invitational: Michigan St. vs. California, Semifinal, Palm Springs, Calif. 4:30 p.m. TRUTV — Acrisure Holiday Invitational: Arizona vs. Vanderbilt, Semifinal, Palm Springs, Calif. 7 p.m. SECN — Western Carolina at Tennessee COLLEGE FOOTBALL 7 p.m. ESPN2 — Toledo at Akron 8 p.m. ESPN — CFP Rankings Show GOLF 4 a.m. (Wednesday) GOLF — Asian Tour: The International Series Qatar, First Round, Doha Golf Club, Doha, Qatar NBA BASKETBALL 7:30 p.m. TNT — Milwaukee at Miami 10 p.m. TNT — L.A. Lakers at Phoenix The Associated Press created this story using technology provided by Data Skrive TV listings provided by LiveSportsOnTV . Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Be the first to know Get local news delivered to your inbox!

How to Watch Top 25 Women’s College Basketball Games – Tuesday, November 26PALERMO, Calif. (AP) — Two children were wounded in a shooting Wednesday at a small religious K-8 school in Northern California and the shooter died from a suspected self-inflicted gunshot, sheriff’s officials said. The children’s conditions were not immediately known. The shooting occurred Wednesday afternoon at the Feather River School of Seventh-Day Adventists, a private, K-8 school in Palermo, a community of 5,500 people about 65 miles (104 km) north of Sacramento. Butte County Sheriff Kory L. Honea said the 911 calls reported “an individual on campus who had fired shots at students,” and said that the shooter did not appear to have a connection to the school. The motive was not immediately known, he continued. One student was flown to a nearby hospital, Honea said. Authorities rushed students to the Oroville Church of the Nazarene to be reunited with their families, the sheriff’s office said. The school has been open since 1965 and caters to fewer than three dozen children, according to its website.We believe this approval fills an important need for patients with NRG1 + cancer who have not previously had treatment options approved to specifically target this driver. BIZENGRI ® (zenocutuzumab-zbco) 20 mg/mL Injection for Intravenous Use is expected to be available to patients in the coming weeks. "The FDA approval of BIZENGRI ® marks an important milestone for patients with pancreatic adenocarcinoma or NSCLC that is advanced unresectable or metastatic and harbors the NRG1 gene fusion. I have seen firsthand how treatment with BIZENGRI ® can deliver clinically meaningful outcomes for patients,” said Alison Schram, MD, an attending medical oncologist in the Early Drug Development Service at Memorial Sloan Kettering Cancer Center and a principal investigator for the ongoing eNRGy trial. "I am extraordinarily grateful for the patients and families who participated in the trial.” "BIZENGRI ® is Merus's first approved medicine based on our highly innovative and proprietary Biclonics ® technology platform and offers significant promise for patients with NRG1 + pancreatic adenocarcinoma and NRG1 + NSCLC,” said Shannon Campbell, Chief Commercial Officer of Merus. "This approval is a testament to both our technology and strong execution as we continue to develop our multispecific platforms and pipeline, including our lead asset petosemtamab.” The approval of BIZENGRI ® is based on data from the eNRGy trial, a multicenter, open-label clinical trial that enrolled patients with NRG1 + pancreatic adenocarcinoma or NRG1 + NSCLC that is advanced unresectable or metastatic and had disease progression on or after prior systemic therapy. In patients with NRG1 + pancreatic adenocarcinoma (n=30), BIZENGRI ® demonstrated an ORR of 40% (95% CI, 23%-59%). DOR in NRG1 + pancreatic adenocarcinoma ranged from 3.7 months to 16.6 months. In the same trial, patients with NRG1 + NSCLC (n=64) who were treated with BIZENGRI ® demonstrated an ORR of 33% (95% CI, 22%-46%). The median DOR in NRG1 + NSCLC was 7.4 months (95% CI, 4.0-16.6). Response rates were measured using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR). In the pooled safety population (N=175), the most common (≥10%) adverse reactions were diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions (IRR), dyspnea, rash, constipation, vomiting, abdominal pain, and edema. The most common Grade 3 or 4 laboratory abnormalities (≥2%) were increased gamma-glutamyltransferase, decreased hemoglobin, decreased sodium, decreased platelets, increased aspartate aminotransferase, increased alanine aminotransferase, increased alkaline phosphatase, decreased magnesium, decreased phosphate, increased activated partial thromboplastin time, and increased bilirubin. "The Personalized Medicine Coalition applauds the approval of BIZENGRI ® , a new targeted therapy for NRG1 + pancreatic adenocarcinoma and NRG1 + NSCLC that are advanced unresectable or metastatic,” said Edward Abrahams, President of the Washington-based education and advocacy organization. "In keeping with the growing number of personalized medicines on the market today, BIZENGRI ® offers the only approved NRG1 + therapy for patients with these difficult-to-treat cancers.” The company plans to help appropriate patients gain access to BIZENGRI ® by providing resources and support based on each patient's needs and situation. PTx AssistTM is available to help guide patients through treatment, from providing educational information to helping to understand insurance coverage and identifying potential financial assistance options. For more information, patients and providers can call 1-844-637-8777, Monday through Friday, from 8:00 a.m. to 8:00 p.m. ET. Please see full Prescribing Information, including Boxed WARNING, at www.BIZENGRI.com/pi . About BIZENGRI ® BIZENGRI ® is a bispecific antibody that binds to the extracellular domains of HER2 and HER3 expressed on the surface of cells, including tumor cells, inhibiting HER2:HER3 dimerization and preventing NRG1 binding to HER3 . BIZENGRI ® decreased cell proliferation and signaling through the phosphoinositide 3-kinase-AKT-mammalian target of rapamycin pathway. In addition, BIZENGRI ® mediates antibody-dependent cellular cytotoxicity. BIZENGRI ® showed antitumor activity in mouse models of NRG1 + lung and pancreatic cancers. 1 About the eNRGy Trial The eNRGy trial (Clinicaltrials.gov NCT02912949) is a multicenter, open-label clinical trial that includes patients with advanced unresectable or metastatic NRG1 + pancreatic adenocarcinoma or NRG1 + NSCLC who have disease progression on or after prior systemic therapy. There were 30 patients in the NRG1 + pancreatic adenocarcinoma group and 64 patients in the NRG1 + NSCLC group. The main outcome measures were ORR and DOR, as determined by BICR according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 1 In the NRG1+ pancreatic adenocarcinoma group, the median age was 49 years (range, 21-72 years); 43% were female; 87% were White, 7% were Asian, and 3.3% were Black or African American. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and all patients had metastatic disease. Patients received a median of 2 prior systemic therapies (range, 0-5); 97% had prior systemic therapy with prior chemotherapy. 1 In the NRG1+ NSCLC group, the median age was 64 years (range, 32-86 years); 64% were female, 33% were White, 56% were Asian, and 3.4% were Black or African American. ECOG performance status was 0 or 1 in 97% of patients or 2 in 3% of patients, and 98% of patients had metastatic disease. Patients received a median of 2 prior systemic therapies (range, 1-6). 1 IMPORTANT SAFETY INFORMATION BOXED WARNING: EMBRYO-FETAL TOXICITY Embryo-Fetal Toxicity: Exposure to BIZENGRI ® during pregnancy can cause embryo-fetal harm. Advise patients of this risk and the need for effective contraception. WARNINGS AND PRECAUTIONS Infusion-Related Reactions/Hypersensitivity/Anaphylactic Reactions BIZENGRI ® can cause serious and life-threatening infusion-related reactions (IRRs), hypersensitivity and anaphylactic reactions. Signs and symptoms of IRR may include chills, nausea, fever, and cough. In the eNRGy study, 13% of patients experienced IRRs, all were Grade 1 or 2; 91% occurred during the first infusion. Administer BIZENGRI ® in a setting with emergency resuscitation equipment and staff who are trained to monitor for IRRs and to administer emergency medications. Monitor patients closely for signs and symptoms of infusion reactions during infusion and for at least 1 hour following completion of first BIZENGRI ® infusion and as clinically indicated. Interrupt BIZENGRI ® infusion in patients with ≤ Grade 3 IRRs and administer symptomatic treatment as needed. Resume infusion at a reduced rate after resolution of symptoms. Immediately stop the infusion and permanently discontinue BIZENGRI ® for Grade 4 or life-threatening IRR or hypersensitivity/anaphylaxis reactions. Interstitial Lung Disease/Pneumonitis BIZENGRI ® can cause serious and life-threatening interstitial lung disease (ILD)/pneumonitis. In the eNRGy study, ILD/pneumonitis occurred in 2 (1.1%) patients treated with BIZENGRI ® . Grade 2 ILD/pneumonitis (Grade 2) resulting in permanent discontinuation of BIZENGRI ® occurred in 1 (0.6%) patient. Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold BIZENGRI ® in patients with suspected ILD/pneumonitis and administer corticosteroids as clinically indicated. Permanently discontinue BIZENGRI ® if ILD/pneumonitis ≥ Grade 2 is confirmed. Left Ventricular Dysfunction BIZENGRI ® can cause left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including BIZENGRI ® . Treatment with BIZENGRI ® has not been studied in patients with a history of clinically significant cardiac disease or LVEF less than 50% prior to initiation of treatment. In the eNRGy study, Grade 2 LVEF decrease (40%-50%; 10 - 19% drop from baseline) occurred in 2% of evaluable patients. Cardiac failure without LVEF decrease occurred in 1.7% of patients, including 1 (0.6%) fatal event. Before initiating BIZENGRI ® , evaluate LVEF and monitor at regular intervals during treatment as clinically indicated. For LVEF of less than 45% or less than 50% with absolute decrease from baseline of 10% or greater which is confirmed, or in patients with symptomatic congestive heart failure (CHF), permanently discontinue BIZENGRI ® . Embryo-Fetal Toxicity Based on its mechanism of action, BIZENGRI ® can cause fetal harm when administered to a pregnant woman. No animal reproduction studies were conducted with BIZENGRI ® . In postmarketing reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death. In animal models, studies have demonstrated that inhibition of HER2 and/or HER3 results in impaired embryo-fetal development, including effects on cardiac, vascular and neuronal development, and embryolethality. Advise patients of the potential risk to a fetus. Verify the pregnancy status of females of reproductive potential prior to the initiation of BIZENGRI ® . Advise females of reproductive potential to use effective contraception during treatment with BIZENGRI ® and for 2 months after the last dose. ADVERSE REACTIONS NRG1 Gene Fusion Positive Unresectable or Metastatic Pancreatic Adenocarcinoma Serious adverse reactions occurred in 23% of patients with NRG1 Gene Fusion Positive Pancreatic Adenocarcinoma who received BIZENGRI ® . There were 2 fatal adverse reactions, one due to COVID-19 and one due to respiratory failure. In patients with NRG1 Gene Fusion Positive Pancreatic Adenocarcinoma who received BIZENGRI ® the most common (≥20%) adverse reactions, including laboratory abnormalities, were increased alanine aminotransferase (51%), diarrhea (36%), increased aspartate aminotransferase (31%), increased bilirubin (31%), decreased phosphate (31%), increased alkaline phosphatase (28%), decreased sodium (28%) musculoskeletal pain (28%), decreased albumin (26%), decreased potassium (26%), decreased platelets (26%), decreased magnesium (24%), increased gamma-glutamyl transpeptidase (23%), decreased hemoglobin (23%), vomiting (23%), nausea (23%), decreased leukocytes (21%), and fatigue (21%). NRG1 Gene Fusion Positive Unresectable or Metastatic NSCLC Serious adverse reactions occurred in 25% of patients with NRG1 Gene Fusion Positive NSCLC who received BIZENGRI ® . Serious adverse reactions in ≥ 2% of patients included pneumonia (n=4) dyspnea and fatigue (n=2 each). Fatal adverse reactions occurred in 3 (3%) patients and included respiratory failure (n=2), and cardiac failure (n=1). Permanent discontinuation of BIZENGRI ® due to an adverse reaction occurred in 3% of patients. Adverse reactions resulting in permanent discontinuation of BIZENGRI ® included dyspnea, pneumonitis and sepsis (n=1 each). In patients with NRG1 Gene Fusion Positive NSCLC who received BIZENGRI ® , the most common (>20%) Adverse Reactions, including laboratory abnormalities, were decreased hemoglobin (35%), increased alanine aminotransferase (30%), decreased magnesium (28%), increased alkaline phosphatase (27%), decreased phosphate (26%) diarrhea (25%), musculoskeletal pain (23%), increased gamma-glutamyl transpeptidase (23%), increased aspartate aminotransferase (22%), and decreased potassium (21%). Please see full Prescribing Information, including Boxed WARNING, at BIZENGRI.com/pi. About Merus N.V. Merus is a clinical stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics ® . Multiclonics ® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus' website https://merus.nl and LinkedIn . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding product development and the potential benefits and treatment impact of BIZENGRI ® (zenocutuzumab-zbco); our belief that this approval fills an important need for patients with NRG1 + cancer who have not previously had treatment options approved to specifically target this driver; the expectation of BIZENGRI ® to be available to patients in the coming weeks; the promise BIZENGRI® holds for patients with NRG1 + pancreatic adenocarcinoma and NSCLC; its implication to our technology and execution as we continue to develop our multispecific platforms and pipeline, including our lead asset petosemtamab; and our expectation to provide patients with access to BIZENGRI ® , as well as offering helpful resources and support based on each patient's needs and situation. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Merus. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or antibody candidates; potential issues associated with regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; our reliance on third parties to conduct our clinical trials, and the potential for those third parties to not perform satisfactorily; impacts of the volatility in the global economy, including global instability, including the ongoing conflicts in Europe and the Middle East; we may not identify suitable Biclonics ® or bispecific antibody candidates under our collaborations, or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent, or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors, and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. These and other important factors discussed under the caption "Risk Factors” in our Quarterly Report on Form 10-Q for the period ended September 30, 2024, filed with the Securities and Exchange Commission, or SEC, on October 31, 2024, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Multiclonics ® , Biclonics ® , Triclonics ® , and BIZENGRI ® are registered trademarks of Merus N.V. Reference: 1. BIZENGRI. Prescribing information. Merus N.V.; 2024. ©2024 Merus N.V. All rights reserved. MAT-0247 V4 12/24 CONTACT: Investor and Media Inquiries: Partner Therapeutics Media Relations 781-786-2405 [email protected] Sherri Spear Merus N.V. SVP, Investor Relations and Strategic Communications 617-821-3246 [email protected] Kathleen Farren Merus N.V. Associate Director, Investor Relations and Corporate Communications 617-230-4165 [email protected]

The Hidden Gem in Gaming Tech! SMCI NASDAQ’s Secret Weapon Revealed

Concerns raised over hospitality staff after smoking curbs ditched

Japan's famous sake joins UNESCO's cultural heritage list, a boost to brewers and enthusiasts

Who killed UnitedHealthcare CEO Brian Thompson? What we know about the suspect on the run

Related hot word search:

Previous: happy jili slot
Next: jili slot 50 minimum deposit